Strategic Partnerships Leverage the Gates Foundation grant and recent collaborations (RetinaRisk integration, maternal health focus) to position Remidio as a partner for global health initiatives and LMIC market entries, offering AI-driven retinal screening as a gateway to broader systemic disease monitoring.

Global Market Validation Capitalize on CE marking, FDA 510(k) registration, and 16 million+ patient screenings across 40+ countries to build credibility with hospital networks, ACOs, and public health programs seeking proven AI ophthalmic solutions.

Product Expansion Expand discussions beyond eye care to systemic disease detection opportunities (CVD, CKD, liver diseases) using retinal imaging AI, targeting enterprise clinics, telemedicine platforms, and maternal health programs in LMICs.

Financing Momentum Utilize recent $25M financing rounds to secure co-development or procurement deals, offering scalable hardware-software packages and favorable terms for large-scale deployments in hospitals and medtech networks.

Recognition & Competitiveness Highlight award wins and top-tier recognitions (AI Impact Summit, MedTech challenges) to differentiate in competitive bids, targeting government procurement, healthcare systems, and insurers seeking innovative Point of Care devices.